What have we learnt from Vioxx?

Krumholz, H. M., Ross, J. S., Presler, A. H., & Egilman, D. S. (2004). What have we learnt from Vioxx?. BMJ.

Type

Journal article

Intellectual base

Primary research

Year

2004

DOI

10.1136/bmj.39024.487720.68

DOI registrant

BMJ

Link

https://doi.org/10.1136/bmj.39024.487720.68

Cited by

1 citation across 1 artifact.

Domain-specific

• Adverse Drug Event
  • Approved in 1999 as a COX-2-selective anti-inflammatory that spared the stomach, it was taken by millions

    SupportedVerified against the source

    Read by an automated reader; not a human review. How support was checked

Verification

Does it exist? Confirmed. This work's DOI resolves to a registered record, which fixes its identity. That is all it fixes.

Does it back the claim? Read against the text for 1 of 1 citation: 1 supported. Each verdict is shown under its citation below, with what in the work backs the sentence.

Support is checked per citation rather than per work — the same source can be cited soundly in one article and wrongly in another. Per-citation recording began recently, so a citation with no recorded check is a gap in the record rather than evidence it went unchecked.

See how references were verified.

Registry ID ref:5fef44f95020 · see in the full table